Tang et al. (2024) demonstrated that the ferroptosis-related gene TFRC inhibits the proliferation and invasion abilities of T24 and UMUC-3 cells. Additionally, TFRC emerges as a potential novel predictive model for OS and immunotherapy efficacy in bladder cancer patients. However, TFRC’s role in CC remains unexplored. Consequently, ferroptosis-based therapy offers a novel approach to enhance the therapeutic effects of cancer chemotherapy and shows promising clinical prospects (Lei et al., 2021; Lin et al., 2022). The gene discussed is TFRC; the disease is urinary bladder carcinoma.